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Abstract  1 
Acrylamide, classified in 1994 by IARC as ‘probably carcinogenic to humans’, was discovered in 2002 2 
in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the 3 
association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent 4 
results. The purpose of this nested case-control study, based on the European Prospective 5 
Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the 6 
association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk 7 
of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in 8 
red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum 9 
(HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC 10 
was evaluated using unconditional multivariable logistic regression models, and included 383 EC 11 
cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on 12 
control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1: 0.84, 13 
95%CI: 0.49-1.48; HRHbGA;Q5vsQ1: 0.94, 95%CI: 0.54-1.63) or type-I EC risk. Additionally, none of the 14 
subgroups investigated (BMI <25 vs ≥25 kg/m2, alcohol drinkers vs never drinkers, oral contraceptive 15 
users vs non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide 16 
or glycidamide were not associated with EC or type-I EC risk in 768 non-smoking postmenopausal 17 
women from the EPIC cohort.  18 
Novelty and impact of the work: In this first epidemiologic study assessing the association between 19 
hemoglobin adduct biomarkers of acrylamide and EC risk, there was no evidence of an increased 20 
risk.   21 
Introduction  22 
The International Agency for Research on Cancer (IARC) classified acrylamide as ‘probably 23 
carcinogenic to humans (group 2A)’ based on evidence from animal and in vitro studies1; however 24 
scientific interest did not increase until 2002, when Swedish researchers reported acrylamide 25 
concentrations in commonly consumed foods2. The principal pathway by which acrylamide is formed 26 
in foods is through the Maillard reaction during food processing at temperatures higher than >120ºC 27 
(i.e. frying or baking)2,3, but acrylamide has also been observed in foods treated at lower 28 
temperatures (e.g., low moisture drying)4. In the European Prospective Investigation into Cancer and 29 
Nutrition (EPIC), the major food contributors to dietary acrylamide intake (based on a 24-h dietary 30 
recall; 24hDR) were bread, crisp bread, rusks, coffee, and potatoes5.  31 
In the human body, acrylamide is conjugated with reduced glutathione for elimination, or is 32 
metabolized to glycidamide through the Cyp2e1 enzyme system. In animal studies, after acrylamide 33 
administration, both hormone- and non-hormone-related tumors have been observed1. Glycidamide 34 
is believed to have mutagenic and genotoxic effects in animals, whereas acrylamide is thought to be 35 
neurotoxic both in animals and in humans3,6, and may also disrupt hormonal homeostasis7,8.  36 
Acrylamide and its metabolite glycidamide can form adducts with hemoglobin (HbAA and HbGA, 37 
respectively), which are stable over the lifespan of erythrocytes (approximately 120 days), and thus, 38 
have been extensively used as biomarkers of human internal exposure3,9. The mean hemoglobin 39 
adduct levels in smokers are at least three to four times higher than non-smokers10, and cigarette 40 
smoke is considered as one of the major sources of acrylamide exposure. Thus, to assess the impact 41 
of dietary acrylamide on health, non-smokers are considered a more suitable population than 42 
smokers.  43 
Cancer of the corpus uteri is the fourth most common incident cancer in European and North 44 
American women. The most common type of corpus uteri cancer is endometrial cancer (EC). The 5-45 
year survival rate of EC is high, ranging from 65 to 85%11. EC has been classified into type-I and type-46 
II tumors; type-I EC is mostly endometrioid adenocarcinoma, and is characterized as an estrogen-47 
dependent tumor. In contrast, type-II EC is usually serous carcinoma, is thought to be estrogen-48 
independent, usually diagnosed in elderly women, and generally has an unfavorable prognosis12,13. 49 
Epidemiological data suggest that obesity, diabetes, low physical activity, long-term exposure to 50 
estrogens, and a history of polycystic ovary syndrome are risk factors for developing EC, and type-I 51 
EC in particular14. Combined oral contraceptive (OC) use, and tobacco smoking are consistently 52 
associated with lower risk of EC14. Further, a recent EPIC study observed an inverse association 53 
between coffee consumption and EC risk15.  54 
To date, four prospective epidemiologic studies, including one from EPIC, have evaluated the 55 
association between dietary intake of acrylamide (assessed through dietary questionnaires; DQs) 56 
and EC risk16–19. Two subsequent meta-analyses concluded that dietary acrylamide intake was not 57 
associated with overall EC risk, but increased risk was observed with higher acrylamide intakes in 58 
women who were never smokers at baseline20,21. To our knowledge, this is the first nested-case 59 
control study within a prospective cohort study designed to assess the relation between circulating, 60 
red blood cell hemoglobin adducts of acrylamide and glycidamide and overall and type-I EC risk.  61 
Material and Methods 62 
The EPIC study comprises 10 European countries and 23 research centers with the aim to evaluate 63 
the association between nutrition and lifestyle factors, cancer and other chronic diseases22. The 64 
current study includes participants from 8 of the 10 EPIC countries: Denmark, Norway, and one 65 
center from Sweden (Malmö) did not participate. For each EPIC center, subjects were followed until 66 
cancer diagnosis (except non-melanoma skin cancer), emigration, death, or end of follow-up, which 67 
varied from December 2005 to June 2010). 68 
The EPIC methodology has been published elsewhere22. Recruitment began between 1992-1998, and 69 
participants reported information on dietary habits (referring to the twelve months before 70 
recruitment) assessed through country-specific, validated dietary questionnaires (DQs). Additionally, 71 
information on tobacco smoking, education, physical activity, anthropometric measures and 72 
reproductive factors was also obtained at recruitment. Blood samples were collected at recruitment 73 
for approximately 80% of the EPIC cohort (385,747 of over 500,000 participants). Samples that were 74 
stored at the IARC bio-bank were kept in liquid nitrogen (-196oC); whereas blood samples from 75 
Umeå were stored at local repositories in freezers (-80oC). The study was approved by the IARC 76 
ethical review boards and/or all local ethics committees. 77 
Blood samples were sent to the Centers for Disease Control and Prevention (CDC) Protein Biomarker 78 
Laboratory to measure HbAA and HbGA. Details of the methodology have been previously 79 
described10. Briefly, adduct levels were measured in 300μL of hemolysed erythrocytes and analyzed 80 
by high-performance liquid chromatography–tandem mass spectrometry (HPLC/MS/MS) in a 81 
randomized manner. Additionally, for each sample two independent measurements were 82 
performed, and results were reported in pmol per g of Hb. The detection limits (LOD) for this 83 
method were 3 and 4 pmol/g Hb for HbAA and HbGA, respectively.  84 
Identification of EC cases was achieved by means of population cancer registries, or through a 85 
combination of methods: health insurance records, cancer and pathology registries, and active 86 
follow-up. EC cases were classified as C54 according to the International Classification of Diseases, 87 
10th revision.   88 
The selection of the study population for the present nested case-control study was based on the 89 
algorithm that has been previously published by Cust et al. and Peeters et al.23: for each EC case two 90 
corresponding controls were randomly selected at the date of diagnosis (subjects free of cancer, 91 
with the exception of non-melanoma skin cancer). Cases and controls were matched by study 92 
center, menopausal status, age at recruitment (±6 months), date at blood collection (± 1 month), 93 
time of the day of blood draw (±1 hour), and fasting status (<3, 3-6, >6 hours). Individual matching 94 
was broken in the present study (one control per case) because we only included women who were 95 
non-smokers, defined as women who reported never smoking or who quit smoking ≥5 years before 96 
recruitment, and who were postmenopausal at blood draw, defined as women who reported not 97 
having menses ≥1 year before recruitment. 98 
A total of 771 subjects (385 EC cases and 386 controls) were included in the study. Of these, three 99 
had to be excluded due to the lack of information on HbAA (n=2 cases) or HbGA (n=1 control), 100 
leaving 383 EC cases and 385 controls included in the final analyses. Only one observation had an 101 
HbGA value below the LOD; thus, we assigned half of the corresponding value of the LOD (2 pmol/g 102 
Hb). Tumor histology was available for 372 (97%) cases, of which 171(46%) were classified as 103 
endometrioid tumors (type-I), 14 (4%) as serous/clear cell tumors (type-II), and 187 (50%) as other 104 
types. ‘Overall EC’ comprises type-I, type-II, and tumors that were classified as others or undefined 105 
for histology. 106 
In order to improve normality of the distributions, all biomarker variables were log-transformed 107 
(log2) and were evaluated as: log2HbAA, log2HbGA, sum of total adducts [log2(HbAA+HbGA)], and 108 
HbGA/HbAA ratio. Additionally, these four continuous variables were categorized into quintiles 109 
based on the distribution in the control group. Unconditional logistic regression models were used to 110 
estimate odds ratios (ORs) and 95% confidence intervals (CI). Analyses were also performed 111 
separately for type-I EC tumors. 112 
All statistical models were adjusted for matching variables (age at recruitment (years), country, date 113 
of blood draw, time of day of the blood draw, and fasting status), and other covariates such as ever 114 
use of OC (never, ever), ever use of hormone replacement therapy (never, ever; HRT), parity 115 
(nulliparous, 1, 2, ≥3, parous but with missing number of full-term pregnancies), age at menopause 116 
(years), body mass index (kg/m2; BMI), and alcohol intake (non-drinkers, drinkers of 0-6, >6-12, >12-117 
24, and >24 g/day). The following variables were evaluated as potential confounders but were not 118 
included in final models because they did not change the risk estimates by >10%: dietary variables 119 
(such as coffee, potatoes, biscuits, crackers, and cakes), history of diabetes (yes, no), age at 120 
menarche (<12, 12, 13, 14, ≥15 years), height (cm), weight (kg), hip circumference (cm), waist 121 
circumference (cm), physical activity using the Cambridge index24, and education level (none, 122 
primary, technical/professional, secondary, and higher education). 123 
Effect-measure modification was evaluated for established risk factors, and for factors considered to 124 
affect the activity of Cyp2e1: BMI (<25 vs ≥25 kg/m2), HRT use (never vs ever users), OC (never vs 125 
ever users), and alcohol intake (never vs ever drinkers )5 using a likelihood ratio test (LRT) based on 126 
categorical biomarker variables. For each biomarker quartile, the median was estimated, and was 127 
included in a score test to evaluate dose-response trends.  128 
The reproducibility of the hemoglobin adducts measurements was assessed using 43 (5%) duplicate 129 
blood samples revealing intraclass correlation coefficients of 0.92 for HbAA and 0.95 for HbGA. All 130 
statistical tests were two-sided and statistical significance was set at p <0.05. All analyses were 131 
performed using SAS v. 9.1 (Cary, North Carolina, USA). 132 
Results 133 
A large number of cases and controls were from Italy and the United Kingdom, and the major 134 
proportion of type-I EC cases were from Germany and The Netherlands (Table 1). The median 135 
interval between the dates at blood collection and diagnosis was 6.2 years. Among cases, the 136 
median (25th–75th percentile) HbAA and HbGA adducts levels were 39.9 (31.4-52.4) and 34.1 (25.7-137 
44.6) pmol/g Hb, respectively; and in controls 39.4 (32.1-51.1) and 33.3 (24.6-43.8) pmol/g Hb, 138 
respectively. As compared with controls, cases were slightly younger, had a slightly higher 139 
proportion of heavy drinking (6.5% vs 5.5%), tended to use less OCs (32.4% vs 36.4%) and more HRT 140 
(27.2% vs 21.6), had higher median BMI values (27.4 vs 26.1 kg/m2), and were more likely to be 141 
nulliparous (16.2% vs 10.9%). Cases and controls had similar ages at menopause.  142 
No associations and no evidence for linear dose-response trends were observed between 143 
biomarkers of dietary acrylamide exposure and overall EC (highest vs lowest quintiles: HRHbAA;Q5vsQ1: 144 
0.85, 95%CI: 0.49-1.46; HRHbGA;Q5vsQ1: 0.94, 95%CI: 0.54-1.63) (Table 2). We also restricted the 145 
analyses to known type-I EC cases and no statistically significant associations were observed (Table 146 
2). Associations between biomarkers of exposure and overall or type-I EC risk were also assessed 147 
using tertiles, quartiles, and deciles (based on the exposure distribution in the control group), and no 148 
significant variations in risk were observed across categories (data not shown). 149 
Subgroup analyses for overall EC were stratified by BMI (<25, ≥25 kg/m2), alcohol intake (never 150 
drinkers, ever drinkers), HRT use (never HRT users, ever HRT users; data not shown), and OC use 151 
(never OC users, ever OC users). No evidence for effect measure modification was observed in any of 152 
the subgroups evaluated (all LRT P-values >0.05) (Table 3). Due to the small sample size, stratified 153 
analyses for type-I EC were conducted using tertiles, and results indicated no heterogeneity (data 154 
not shown).  155 
Discussion 156 
The present nested case-control study within the EPIC cohort is the first epidemiologic study to 157 
evaluate the association between biomarkers of acrylamide exposure and endometrial cancer risk. 158 
We did not observe any evidence to support the hypothesis that levels of biomarkers of acrylamide 159 
and glycidamide exposure measured as hemoglobin adducts (HbAA, HbGA, sum of total adducts, and 160 
HbGA/HbAA ratio) were associated with the risk of developing overall EC or type-I EC in non-smoking 161 
postmenopausal women. Furthermore, there was no evidence for effect measure modification by 162 
BMI, alcohol intake, HRT use, or OC use though there was relatively limited power to assess 163 
heterogeneity among subgroups. 164 
The present study was based on a subgroup of non-smoking postmenopausal women in the EPIC 165 
cohort to address two major concerns. First, tobacco smoking is considered one of the major sources 166 
of acrylamide exposure, and it is recognized that smokers have higher levels of acrylamide 167 
biomarkers10; second, hormonal homeostasis may be disrupted by acrylamide7,8, thus, the analyses 168 
were performed in non-smoking postmenopausal women only.  169 
The lack of association between biomarkers of acrylamide exposure and overall and type-I EC risk is 170 
in agreement with results we previously reported in the EPIC sub-cohort of women, where hazard 171 
ratios were estimated for the association between dietary acrylamide intake (assessed through DQs ) 172 
and overall EC (n=1382) or type-I EC risk (n=627); nevertheless, in the full cohort analysis, positive 173 
associations were reported between acrylamide intake and type-I EC risk in women who were never 174 
smokers and non-users of OCs19. In the present study, using circulating biomarkers of acrylamide 175 
exposure, we did not replicate these results possibly due to the small sample size with tumor 176 
histology information (n=171 type-I EC cases). Additionally, the null results based on FFQ data 177 
reported by the Swedish Mammography Cohort study17 are also in line with the results presented in 178 
the current study. However, the Netherlands Cohort Study reported hazard ratios for dietary 179 
acrylamide intake and risk of EC of 1.29 (95%CI: 0.81-2.07; P-trend: 0.18) and 1.99 (95%CI: 1.25-3.52; 180 
P-trend: 0.03) in the entire cohort and in never smoking women, respectively16. The Nurses’ Health 181 
Study also reported relative risks for dietary acrylamide intake of 1.41 (95%CI: 1.01-1.97; P-trend: 182 
0.03) and 1.43 (95%CI: 0.90-2.28; P-trend: 0.04) in the entire cohort and in never smoking women18. 183 
Two recent meta-analyses concluded that higher consumption of dietary acrylamide was 184 
significantly associated with overall EC risk in never smoking women; but not in all women combined 185 
20,21. In the present study of acrylamide and glycidamide biomarkers and EC risk in non-smoking 186 
postmenopausal women, we did not observe any evidence for associations with overall or type-I EC 187 
risk.  188 
The main strengths of the present nested case-control study are its study design, with the intention 189 
to prevent confounding from tobacco smoking and hormonal fluctuations, and the use of 190 
prospective information on the main risk factors for EC. The minimum detectable ORs at 80% power 191 
in our study were 1.22 and 1.60 for the continuous and categorical variables, respectively. 192 
Moreover, measurement errors from using acrylamide intake estimates based on FFQs were 193 
avoided, and the quantification of HbAA and HbGA was performed following rigorous quality 194 
assurance/quality control laboratory protocols10; and all blood samples were drawn from 195 
participants before disease diagnosis. The present study also had limitations: (a) a single blood 196 
sample was collected at baseline for each observation, thus, we were not able to measure intra-197 
individual variability in adduct measurements. Hemoglobin adducts of acrylamide and glycidamide 198 
reflect exposure to acrylamide within the past 4 months, thus, a single measurement may not 199 
capture long-term average exposure in the presence of high intra-individual variability. In a small 200 
study of 13 participants Vikström et al. observed high intra-individual variability (up to 2-fold and 4-201 
fold differences in HbAA and HbGA levels, respectively) over a period of 20 months 25. By contrast, 202 
the NHS-II study observed lower intra-individual variability for Hb-adduct measurements (intra-203 
individual correlation= 0.78, 0.80, and 0.77 for HbAA, HbGA, and sum of HbAA+HbGA, respectively) 204 
from 45 non-smoking women at two time-points separated by a median of 23 months 26. (b) 205 
Although all models accounted for matching variables as well as known EC risk factors, we cannot 206 
exclude the possibility of residual confounding in our analyses. (c) Further, variables for second-hand 207 
smoke (SHS) exposure could not be evaluated in statistical models due to the large number of 208 
missing values (>50%). In a subset of the present study with available data, no statistically significant 209 
differences in Hb-adducts levels were observed between controls who reported not being exposed 210 
to SHS (n=80) and controls who were exposed to SHS (n=53) (data not presented). Moreover, two 211 
additional studies reported null or negligible effects of SHS on biomarkers of acrylamide exposure 212 
27,28. (d) Despite having information on tumor histology for 97% of the EC cases (of which 46% were 213 
classified as type-I), we were not able to analyze type-II EC due to the small sample size (n=14).   214 
In conclusion, this study does not provide evidence of an association between levels of hemoglobin 215 
adducts of acrylamide and glycidamide and risks of overall EC and type-I EC.  216 
   217 
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Tables  1 
Table 1. Description of the study population from a nested case-control study of acrylamide biomarkers and EC in the EPIC cohort 
  
All EC cases Type-I Cases Controls 
n=383 n=171 n=385 
HbAA (pmol/g Hb) a 39.9 (31.4-52.4) 40.1 (31.4-52.8) 39.4 (32.1-51.1) 
HbGA (pmol/g Hb) a 34.1 (25.7-44.6) 33 (25.3-46.2) 33.3 (24.6-43.8) 
HbAA+HbGA (pmol/g Hb) a 74.4 (57.5-97.6) 72.5 (56.8-97.8) 72.8 (57.2-94.5) 
HbGA/HbAA (pmol/g Hb) a 0.9 (0.7-1.0) 0.8 (0.7-1.0) 0.8 (0.7-1.0) 
Age at recruitment (y) a 58.0 (53.5-61.4) 57.7 (53.6-61.0) 58.5 (54.3-61.7) 
Age at menopause (y) a 49.5 (49.5-52.0) 49.5 (49.5-52.0) 49.5 (49.0-52.0) 
BMI (Kg/m2) a 27.4 (24.1-31.6) 27.4 (24.4-33.2) 26.1 (23.2-29.3) 
Country b  
   France 33 (8.6) 17 (9.9) 35 (9.1) 
Italy 69 (18.0) 24 (14.0) 74 (19.2) 
Spain 55 (14.4) 25 (14.6) 72(18.7) 
United Kingdom 70 (18.3) 30 (17.5) 60 (15.6) 
The Netherlands 56 (14.6) 32 (18.7) 38 (9.9) 
Greece 13 (3.4) 3 (1.8) 16 (4.2) 
Germany 51 (13.3) 40 (23.4) 56 (14.6) 
Sweden 36 (9.4) 0 (0.0) 34(8.8) 
Fasting statusb 
   Unknown 1 (0.3) 1 (0.6) 0 (0.0) 
<3 hours 150 (39.2) 77 (45.0) 129 (33.5) 
3-6 hours 60 (15.7) 34 (19.9) 64 (16.6) 
>6 hours 172 (44.9) 59 (34.5) 192 (49.9) 
Alcohol consumption b 
   Non drinker 94 (24.5) 37 (21.6) 93 (24.2) 
>0-6 g/day 168 (43.9) 72 (42.1) 166 (43.1) 
>6-12 g/day 63 (16.5) 32 (18.7) 67 (17.4) 
>12-24 g/day 33 (8.6) 19 (11.1) 38 (9.9) 
>24-60 g/day 25 (6.5) 11 (6.4) 21 (5.5) 
Ever use of OCb 
   Unknown 10 (2.6) 1 (0.6) 8 (2.1) 
No 249 (65.0) 102 (59.7) 237 (61.6) 
Yes 124 (32.4) 68 (39.8) 140 (36.4) 
Ever use of HRT b 
   Unknown 16 (4.2) 5 (2.9) 15 (3.9) 
No 263 (68.7) 114 (66.7) 287 (74.6) 
Yes 104 (27.2) 52 (30.4) 83 (21.6) 
Parity b 
   Unknown 61 (4.4) 31 (2.3) 59 (2.3) 
1 child 130 (15.9) 62 (18.1) 140 (15.3) 
2 children 105 (33.9) 46 (36.3) 131 (36.4) 
>=3 children 62 (27.4) 21 (26.9) 42 (34.0) 
Nulliparous 8 (16.2) 7 (12.3) 4 (10.9) 
Parous but with missing number of full-term pregnancies 17 (2.1) 4 (4.1) 9 (1.0) 
EC, endometrial cancer; EPIC, European Prospective Investigation into Cancer and Nutrition; HbAA, hemoglobin adducts of acrylamide; HbGA, 
hemoglobin adducts of glycidamide, BMI, body mass index; OC, oral contraceptive; HRT, hormone replacement therapy. 
a Median and quartile range (25th – 75th percentile). 
b number (n) and percent (%). 
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Table 2. OR and 95% CI for biomarkers of acrylamide exposure and EC risk in a nested case-control study in the 
EPIC cohort 
Overall EC  Type 1 EC 
Exposure Cut points 
Cases Controls 
OR (95%CI) 
P- Cases Controls 
OR (95%CI) 
P- 
n=383 n=385 trend n=171 n=385 trend 
H
b
A
A
 
≤29.4 77 74 1.00 (ref) 
0.94 
33 74 1.00 (ref) 
0.94 
29.5-36.1 75 80 0.82( 0.49- 1.37) 33 80 0.94( 0.49- 1.84) 
36.2-43.6 74 77 0.96( 0.57- 1.61) 36 77 1.21( 0.62- 2.36) 
43.7-54.3 73 77 0.87( 0.51- 1.48) 30 77 0.96( 0.49- 1.92) 
>54.3 84 77 0.85( 0.49- 1.46) 39 77 0.96( 0.48- 1.92) 
 
Continuous  
  
 
1.00( 0.99- 1.01)   
  
 
1.00( 0.99- 1.02) 
 
  Continuous-Log2 1.00( 0.68- 1.47)   1.03( 0.62- 1.70)   
H
b
G
A
 
≤23 56 76 1.00 (ref) 
0.74 
29 76 1.00 (ref) 
0.92 
23.1-29.4 85 78 1.28( 0.76- 2.15) 42 78 1.31( 0.68- 2.52) 
29.5-37.6 87 77 1.20( 0.71- 2.04) 30 77 1.01( 0.51- 2.01) 
37.7-46.9 75 77 1.06( 0.62- 1.83) 29 77 1.03( 0.52- 2.06) 
>46.9 80 77 0.94( 0.54- 1.63) 41 77 1.06( 0.53- 2.12) 
 
Continuous  
  
 
1.00( 0.98- 1.01)   
  
 
1.00( 0.99- 1.01) 
 
  Continuous-Log2 0.92( 0.66- 1.28)   1.00( 0.66- 1.50)   
Su
m
 o
f 
H
b
A
A
 +
 
H
b
G
A
 
≤53.6 67 77 1.00 (ref) 
0.95 
34 77 1.00 (ref) 
0.97 
53.7-66.3 81 76 1.16( 0.69- 1.96) 38 76 1.15( 0.59- 2.23) 
66.4-81.8 78 78 0.99( 0.59- 1.67) 30 78 0.91( 0.47- 1.78) 
81.9-100.2 73 77 1.05( 0.61- 1.81) 29 77 0.98( 0.49- 1.96) 
>100.2 84 77 0.95( 0.55- 1.63) 40 77 0.97( 0.49- 1.91) 
 
Continuous  
  
 
1.00( 0.99- 1.01)   
  
 
1.00( 0.99- 1.01) 
 
  Continuous-Log2 0.97( 0.67- 1.41)   1.02( 0.64- 1.63)   
R
at
io
 o
f 
H
b
G
A
/H
b
A
A
 ≤0.69 62 76 1.00 (ref) 
0.16 
27 76 1.00 (ref) 
0.02 
0.70-0.80 92 78 1.29( 0.78- 2.14) 49 78 1.93( 1.01- 3.69) 
0.81-0.88 57 73 0.72( 0.42- 1.26) 24 73 0.75( 0.36- 1.56) 
0.89-0.98 73 78 0.79( 0.46- 1.35) 29 78 0.81( 0.39- 1.68) 
>0.98 99 80 1.08( 0.64- 1.84) 42 80 1.45( 0.73- 2.88) 
  Continuous      0.82( 0.26- 2.54)       0.99( 0.19- 5.05)   
OR, odds ratio; CI, confidence interval; EC, endometrial cancer; EPIC, European Prospective Investigation into Cancer 
and Nutrition; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide. 
All models are adjusted for age at recruitment, country, fasting status, date at blood collection, time of the day of 
blood collection, OC use, HRT use, alcohol intake, parity, age at menopause, and BMI. 
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Table 3. Stratified analyses: OR and 95% CI for biomarkers of acrylamide exposure and EC risk in a nested case-control study in the EPIC cohort 
  
  <25 kg/m2 ≥25 kg/m2 Never drinkers Drinkers Non-Oral contraceptive users Oral contraceptive users 
Cutpoints 
Case
s 
Control
s 
OR (95%CI)a 
Case
s 
Control
s 
OR (95%CI)a 
Case
s 
Control
s 
OR (95%CI)b 
Case
s 
Control
s 
OR (95%CI)b 
Case
s 
Control
s 
OR (95%CI)c 
Case
s 
Control
s 
OR (95%CI)c 
H
b
A
A
 
≤30.3 18 21 1.00 (ref) 59 53 1.00 (ref) 21 20 1.00 (ref) 56 54 1.00 (ref) 56 56 1.00 (ref) 19 18 1.00 (ref) 
30.4-37.6 25 32 0.79( 0.29- 2.15) 50 48 0.91( 0.49- 1.71) 21 18 1.32( 0.47- 3.69) 54 62 0.71( 0.39- 1.31) 46 48 0.87( 0.47- 1.63) 29 30 0.85( 0.30- 2.40) 
37.7-45.3 18 40 0.47( 0.17- 1.35) 56 37 1.37( 0.72- 2.60) 14 22 0.66( 0.22- 1.97) 60 55 1.06( 0.58- 1.95) 47 45 0.98( 0.52- 1.84) 25 30 0.96( 0.34- 2.74) 
45.4-56.0 27 27 1.03( 0.35- 3.01) 46 50 0.60( 0.31- 1.16) 16 20 0.98( 0.31- 3.03) 57 57 0.88( 0.47- 1.66) 43 43 0.92( 0.47- 1.79) 26 31 0.72( 0.25- 2.03) 
>56.0 30 34 0.84( 0.29- 2.41) 54 43 0.87( 0.44- 1.70) 22 13 1.24( 0.36- 4.28) 62 64 0.75( 0.40- 1.41) 57 45 1.13( 0.58- 2.20) 25 31 0.62( 0.21- 1.83) 
LRTd 0.06 0.42 0.63 
H
b
G
A
 
≤23 21 26 1.00 (ref) 35 50 1.00 (ref) 7 15 1.00 (ref) 49 61 1.00 (ref) 40 48 1.00 (ref) 16 27 1.00 (ref) 
23.1-29.4 26 37 0.75( 0.30- 1.87) 59 41 1.88( 0.98- 3.62) 29 18 3.89( 1.11- 13.71) 56 60 0.97( 0.54- 1.75) 50 52 0.93( 0.49- 1.77) 35 24 2.89( 1.08- 7.75) 
29.5-37.6 31 36 0.60( 0.24- 1.54) 56 41 1.73( 0.87- 3.44) 14 22 1.13( 0.30- 4.18) 73 55 1.33( 0.74- 2.40) 55 41 1.36( 0.70- 2.64) 27 33 1.30( 0.48- 3.52) 
37.7-46.9 19 27 0.54( 0.19- 1.59) 56 50 1.38( 0.71- 2.69) 19 23 1.62( 0.44- 6.00) 56 54 1.02( 0.55- 1.89) 49 49 1.00( 0.51- 1.98) 23 27 1.75( 0.62- 4.95) 
>46.9 21 28 0.55( 0.19- 1.59) 59 49 1.25( 0.63- 2.49) 25 15 2.17( 0.54- 8.79) 55 62 0.76( 0.41- 1.42) 55 47 1.16( 0.58- 2.30) 23 29 0.78( 0.27- 2.30) 
LRTd 0.35 0.05 0.07 
Su
m
 o
f 
H
b
A
A
 +
 H
b
G
A
 
≤53.6 20 24 1.00 (ref) 47 53 1.00 (ref) 14 17 1.00 (ref) 53 60 1.00 (ref) 49 55 1.00 (ref) 18 22 1.00 (ref) 
53.7-66.3 24 33 0.91( 0.34- 2.46) 57 43 1.41( 0.75- 2.65) 26 19 2.17( 0.69- 6.76) 55 57 0.93( 0.50- 1.71) 46 45 1.19( 0.63- 2.27) 33 28 1.30( 0.47- 3.54) 
66.4-81.8 24 41 0.48( 0.18- 1.27) 54 37 1.48( 0.76- 2.89) 12 21 0.80( 0.25- 2.63) 66 57 1.10( 0.61- 2.01) 51 45 1.10( 0.58- 2.10) 24 31 0.90( 0.33- 2.48) 
81.9-
100.2 
26 25 1.04( 0.36- 2.98) 47 52 0.86( 0.44- 1.67) 17 23 1.07( 0.32- 3.55) 56 54 1.09( 0.59- 2.03) 45 44 1.21( 0.62- 2.37) 25 31 0.89( 0.32- 2.50) 
>100.2 24 31 0.76( 0.27- 2.20) 60 46 1.09( 0.56- 2.12) 25 13 1.64( 0.45- 6.00) 59 64 0.80( 0.43- 1.48) 58 48 1.25( 0.64- 2.42) 24 28 0.65( 0.22- 1.89) 
LRTd 0.09 0.14 0.68 
R
at
io
 o
f 
H
b
G
A
/H
b
A
A
 
≤0.69 34 40 1.00 (ref) 28 36 1.00 (ref) 8 13 1.00 (ref) 54 63 1.00 (ref) 38 37 1.00 (ref) 23 37 1.00 (ref) 
0.70-0.80 35 39 1.14( 0.51- 2.53) 57 39 1.63( 0.79- 3.35) 24 13 2.79( 0.75- 10.34) 68 65 1.08( 0.62- 1.88) 56 48 1.05( 0.54- 2.06) 35 28 2.47( 1.03- 5.94) 
0.81-0.88 14 30 0.45( 0.17- 1.16) 43 43 1.10( 0.52- 2.30) 8 18 0.44( 0.10- 1.86) 49 55 0.81( 0.44- 1.48) 35 42 0.63( 0.31- 1.31) 20 29 1.10( 0.42- 2.87) 
0.89-0.98 16 22 0.63( 0.22- 1.79) 57 56 1.03( 0.51- 2.07) 18 25 0.69( 0.19- 2.48) 55 53 0.83( 0.45- 1.52) 51 56 0.73( 0.37- 1.46) 21 22 1.17( 0.44- 3.11) 
>0.98 19 23 0.75( 0.27- 2.07) 80 57 1.59( 0.80- 3.17) 36 24 1.12( 0.33- 3.82) 63 56 1.01( 0.55- 1.86) 69 54 1.06( 0.53- 2.10) 25 24 1.25( 0.47- 3.37) 
LRTd 0.76 0.16 0.56 
OR, odds ratio; CI, confidence interval; EC, endometrial cancer; EPIC, European Prospective Investigation into Cancer and Nutrition; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide. 
a Adjusted for age at recruitment, country, fasting status, date at blood collection, OC use, HRT use, alcohol intake, parity,  and age at menopause. 
b Adjusted for  age at recruitment, country, fasting status, date at blood collection, OC use, HRT use, parity, age at menopause, and BMI. 
c Adjusted for  age at recruitment, country, fasting status, date at blood collection, HRT use, alcohol intake, parity, age at menopause, and BMI. 
d All LRT P-values for effect measure modification are based on the categorical exposure adduct variable. 
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